Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | 阶段
第二阶段
|
Date Added 2024-06-12 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06566755 |
TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | 阶段
第三阶段
|
Date Added 2024-08-22 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | 阶段
第 1 阶段
|
Date Added 2023-01-05 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, Regorafenib |
标签
MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2024-03-29 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Balstilimab, Botensilimab |
标签
MSS/ MMRp
|
| NCT ID NCT02343991 |
TitleBlood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound | 阶段
不适用
|
Date Added 2015-01-22 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Transcranial ExABlate |
标签
MSS/ MMRp
|
| NCT ID NCT01061515 |
TitleBiweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2010-02-03 |
地点
Missouri, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda |
标签
MSS/ MMRp
|
| NCT ID NCT03740256 |
Title二元溶瘤腺病毒与 HER2 特异性自体 CAR VST 联合治疗晚期 HER2 阳性实体瘤 | 阶段
第 1 阶段
|
Date Added 2018-11-14 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
CAdVEC |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03851614 |
TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2019-02-22 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cediranib, durvalumab, Olaparib |
标签
MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | 阶段
Phase 1, Phase 2
|
Date Added 2017-07-14 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
标签
MSS/ MMRp
|
| NCT ID NCT03608046 |
TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | 阶段
第二阶段
|
Date Added 2018-07-31 |
地点
比利时
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Avelumab, Cetuximab Injection, Irinotecan |
标签
MSS/ MMRp
|
